Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Prevenção do uso de substâncias baseadas em atenção plena (Minds-up) (MINDS-UP)

22 de setembro de 2026 atualizado por: David Saunders, MD PhD, New York State Psychiatric Institute

Prevenção do uso de substâncias baseadas em atenção plena (Minds-up): um estudo controlado randomizado

The goal of this clinical trial is to test the feasibility, behavioral/neural mechanisms, and preliminary efficacy of "MINDfulness-based Substance Use Prevention Program," or "MINDS-UP", a novel substance use prevention meditation intervention for children and adolescents between the ages of 10 and 14. The aims of the study are:

Aim 1: Determine feasibility and acceptability of MINDS-UP as a preventive intervention via a) retention, b) attendance, c) teacher-rated participation, d) student-rated participation, e) homework completion, and f) acceptability.

Aim 2: Evaluate neuropsychological mechanisms (target engagement) of MINDS-UP.

Aim 3 (Exploratory): Assess preliminary efficacy of MINDS-UP on substance use initiation (SUI).

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Tipo de estudo

Intervencional

Inscrição (Estimado)

40

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

10 anos a 14 anos (Filho)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Youth is ages 10-14 years on the day of screening [i.e., does not turn 15 before or on the day of screening]
  2. Youth has access to a smartphone, tablet, or computer with Wi-Fi
  3. Youth and parent are English-speaking

Exclusion Criteria:

1. The youth has been diagnosed with or received treatment for one of the following mental health problems: depression, bipolar disorder, schizophrenia, autism spectrum disorder, intellectual disability, or substance use disorder.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Prevenção
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Sport: Prevention Plus Wellness (PPW)

Sport: Prevention Plus Wellness (PPW) is a brief, evidence-based substance use prevention program for youth. PPW consists of a single self-administered 45-minute session that is interactive and intended for use by youth in the home setting. It involves screening youth to increase awareness of their current health behaviors; motivational enhancement for change; and establishing a behavior goal plan.

PPW is a standardized, empirically-based intervention for substance use prevention in adolescents ages 10-14. It consists of 1 45 minute self-administered online course.

Outros nomes:
  • Ppw
Experimental: PPW + MINDS-UP

MINDS-UP consists of 4 x 60-minute sessions, once weekly over 4 weeks. MINDS-UP will be delivered to participants remotely, in a 1:1 setting, taught by the meditation teachers that will be hired and trained by Dr. Saunders. Additionally, participants will be provided audio files of 5-10-minute guided meditation practices, led by Dr. Saunders, as homework. Participants randomized to MINDS-UP will also complete PPW, a 45 minute, self-administered course.

PPW is a standardized, empirically-based intervention for substance use prevention in adolescents ages 10-14. It consists of 1 45 minute self-administered online course.

Outros nomes:
  • Ppw

MINDS-UP is a substance use prevention program for children/adolescents.It consists of 4 x 60-minute sessions, once weekly over 4 weeks. The four MINDS-UP classes will focus on the following: Mindfulness of Body; Mindfulness of Mind; Mindfulness of Environment/Community; Kindness, Compassion, Joy and Equanimity, respectively.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Retention
Prazo: Completion of Study (up to 36 months)

Percent of participants who completed all study procedures among those who were randomized

Completion of Study (up to 36 months)
Attendance
Prazo: Completion of Study (up to 36 months)

Percent of scheduled sessions that were completed by the participant.

Completion of Study (up to 36 months)
Teacher Rated Participation
Prazo: Completion of Study (up to 36 months)

Research Assessment Package for Schools - Teacher Rated

Completion of Study (up to 36 months)
Student-Rated Participation
Prazo: Completion of Study (up to 36 months)

Research Assessment Package for Schools - Student Engagement

Completion of Study (up to 36 months)
Homework Completion
Prazo: Completion of Study (up to 36 months)

Percentage of assigned homeworks that were completed by the participant.

Completion of Study (up to 36 months)
Acceptability
Prazo: Completion of Study (up to 36 months)

Acceptability of Intervention Measure

Completion of Study (up to 36 months)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Total Problems (parent-report)
Prazo: 4-8 weeks, 6 months, and 12 months

Pre-assessment to post-assessment (and 6- and 12-month follow-up) difference in the total score on the total problems subscale on the Child Behavior Checklist (CBCL), which is comprised of 98 questions; individual item scores range from 0 to 2; higher scores indicate higher amount of behavioral problems

4-8 weeks, 6 months, and 12 months
ADHD Symptoms
Prazo: 4-6 weeks, 6 months, and 12 months

Pre-assessment to post-assessment (and 6- and 12-month follow-up) difference in score on the ADHD Rating Scale, an 18-item parent-report assessment that measures adolescent behaviors related to ADHD (inattentiveness, hyperactivity).

4-6 weeks, 6 months, and 12 months
Suicidal Thoughts/Behaviors
Prazo: 4-6 weeks, 6 months, 12 months

The C-SSRS is a gold-standard assessment tool for suicide risk. This tool will be administered at every visit.

4-6 weeks, 6 months, 12 months
Alcohol sipping
Prazo: 4-6 weeks, 6 months, and 12 months

Low-level and early alcohol use as characterized by the iSay Sipping Inventory. This survey characterizes low level and first/early alcohol use, including age at first sip, whether that drink was completed, and behaviors after the first sip.

4-6 weeks, 6 months, and 12 months
Tobacco Use
Prazo: 4-6 weeks, 6 months, and 12 months

Tobacco use as measured by Tobacco Low Level Use Measure. This is a short tool that measures number of times used, type of tobacco/nicotine used, duration of use, and frequency of use.

4-6 weeks, 6 months, and 12 months
Cannabis Use
Prazo: 4-6 weeks, 6 months, and 12 months

Cannabis use as measured by the Marijuana Low-Level Use Measure, a short tool that measures early/first use of cannabis.

4-6 weeks, 6 months, and 12 months
Total Problems (adolescent report)
Prazo: 4-6 weeks, 6 months, 12 months

The Youth Self Report (YSR) is the self-report adolescent version of the Child Behavior Checklist, and is used to assess emotional and behavioral problems in children and adolescents.

4-6 weeks, 6 months, 12 months
Mindfulness
Prazo: 4-6 weeks, 6 months, and 12 months

Pre-assessment to post-assessment (and 6- and 12-month follow-up) difference in score on the Child and Adolescent Mindfulness Measure (CAMM); the CAMM is a 10-item measure of self-reported mindfulness; scores range from 0 to 40, with higher scores indicating higher mindfulness

4-6 weeks, 6 months, and 12 months
Anxiety and Depression
Prazo: 4-6 weeks, 6 months, and 12 months

Pre-assessment to post-assessment (and 6 and 12 month-follow-up) difference in score on the Revised Childhood Anxiety and Depression scale, a 47-item self-report scale that assesses childhood/adolescent anxiety and depression symptoms across six sub-domains.

4-6 weeks, 6 months, and 12 months
Perceived Tolerance of Use
Prazo: baseline

The Perceived Tolerance of Use is a tool that assesses peer tolerance of use of substance use (of substances that a participant has heard of, meaning the number of items is variable). It is a tool that is used in the ABCD study and the Monitoring the Future Study, the two most comprehensive studies of adolescent substance use.

baseline
Perceived Harm of Substance Use
Prazo: baseline

The Perceived Harm of Substance Use tool assesses perceived harm of substance use (of substances that a participant has heard of, meaning the number of items is variable). It is used in the ABCD study and the Monitoring the Future Study, the two most comprehensive studies of adolescent substance use.

baseline
Beliefs About Alcohol Effects
Prazo: baseline

The Brief Comprehensive Effects of Alcohol Questionnaire is a 15-item self-report version of the Comprehensive Effects of Alcohol Questionnaire that is used by the ABCD study to assess an adolescent's expectations of using alcohol.

baseline
Beliefs About Smoking Effects
Prazo: baseline

The Adolescent Smoking Consequences Questionnaire (ASCQ) is a 30-item self-report instrument used to assess outcome expectancies of cigarette smoking among adolescents.

baseline
Beliefs About Cannabis Effects
Prazo: baseline

Brief -Marijuana Effect Expectancies Questionnaire (MEEQ-B) is a 6-item self-report assessment of an adolescent's expected effect of marijuana.

baseline
Risk and Protective Factors
Prazo: Baseline

The Community Risk and Protective Factors Survey is a 24-item parent-report tool to assess adolescent's experience of exposure to substance use risk and protective factors in the community.

Baseline

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de outubro de 2026

Conclusão Primária (Estimado)

1 de janeiro de 2028

Conclusão do estudo (Estimado)

1 de janeiro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

15 de agosto de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

9 de setembro de 2024

Primeira postagem (Real)

19 de setembro de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

25 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

22 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • #Pro00076319
  • K12DA000357 (Concessão/Contrato do NIH dos EUA)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever